Biotech entity
pharma is the sole category represented across all 2 tracked stories. Ameluz is most often covered alongside Biofrontera Inc., which appears in 2 of these 2 stories. At 5, the average consequence score sits below the same-window beat average of 6.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. Ameluz is most often covered alongside Biofrontera Inc., which appears in 2 of these 2 stories. At 5, the average consequence score sits below the same-window beat average of 6. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. Ameluz appears in 2 tracked Biotech stories from March 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ameluz. Shared-story counts are live from our verified record — not editorial picks.
Biofrontera and DarioHealth reported Q4 2025 results that underscore a strategic shift toward high-margin clinical and enterprise markets. Both companies are prioritizing a path to profitability through disciplined cost management and the expansion of recurring revenue streams in dermatology and digital chronic care.
Biofrontera Inc. (BFRI) has achieved record financial results for the fourth quarter and full year 2025, signaling a significant shift in the dermatology market toward photodynamic therapy. The company's performance reflects robust adoption of its flagship product, Ameluz, and its proprietary RhodoLED lamp technology in the United States.
Ameluz is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
